We work Hard to get you posted with latest updates

http://We%20work%20Hard%20to%20get%20you%20posted%20with%20latest%20updates

Spend time learning about the different aspects of that topic from experts in the field.

Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy

Unwrap our new Directory

http://Unwrap%20our%20new%20Directory

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

Life Sciences Cloud

Advertisement

cGxPJobs Banner

Haleon Adopts Salesforce AI Cloud to Transform Customer Engagement

LONDON, Oct. 8, 2025 — Haleon, the world’s largest pure-play consumer health company, has partnered with Salesforce to deploy...

By cGxPwire Editor
October 8, 2025

Read More

Advertisement

cGxPJobs

Recent Posts

01

.Clinical

Novo Nordisk Oral Semaglutide Shows Pediatric Breakthrough
April 24, 2026
02

.Tech

Merck Partners with Google Cloud for $1B AI Platform
April 24, 2026
03

Pharma

Regeneron & Sanofi Secure FDA Approval for Dupixent in Pediatric CSU
April 24, 2026
04

M&A

Dogwood Therapeutics Secures $100M Partnership for Antiviral Assets
April 24, 2026
05

M&A

Atrium Therapeutics Earns $15M Milestone from Bristol Myers Squibb
April 24, 2026

Advertisement

Copyright © 2026 cGxP.wire | Made by 3styler

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

Start typing and press Enter to search

Loading Comments...

Write a Comment...

Email (Required)

Name (Required)

Website